VIR Stock – Barclays Stick to Their Buy Rating for Vir Biotechnology By Fintech Zoom
Barclays (LON:) analyst Gena Wang maintained a Buy rating on Vir Biotechnology (NASDAQ:) on Thursday, setting a price target of $96, which is approximately 55.26% above the present share price of $61.83.
Wang expects Vir Biotechnology to post earnings per share (EPS) of -$0.83 for the first quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Vir Biotechnology, with an average price target of $81.4.
The analysts price targets range from a high of $135 to a low of $30.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $1.73 million and a net profit of -$108.4 million. The company’s market cap is $7.9 billion.
According to TipRanks.com, Barclays analyst Gena Wang is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 23.3% and a 53.59% success rate.
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.
Fintech Zoom or anyone involved with Fintech Zoom will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.